Stock listing

Munich:7XP Organon & Co. Aktie

German listing (Munich) of Organon & Co. · home listing NYSE:OGN

Follow Organon & Co. into a list and get an email when it puts out news.

Share price · MUN:7XP

€12.27 EUR +0.04 (+0.3%)

Close on Oct 27, 2026

Day range
€12.27 – €12.27 EUROct 27, 2026
Market cap
€6.47B EURAt the close on Oct 27, 2026 · price × 527.3M shares outstanding
Organon & Co. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:OGN · Home$13.82 USD-0.02 (-0.1%)2,147,179$13.85$13.85$13.82$13.84Close on Nov 2, 2026
LSE:0A9W$13.77 USD+0.02 (+0.1%)881$13.77$13.78$13.73$13.75Close on Oct 27, 2026
Frankfurt:7XP€12.30 EUR+0.055 (+0.4%)—€12.29€12.35€12.29€12.24Close on Oct 27, 2026
Munich:7XP€12.27 EUR+0.038 (+0.3%)—€12.27€12.27€12.27€12.24Close on Oct 27, 2026
Ticker
Munich:7XP
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Organon & (NYSE:OGN) Q4 2025 Earnings Call

    Thu, Feb 12, 2026 · 8:30 AM ET

    Watch Transcript

  • Organon & (NYSE:OGN) Q3 2025 Earnings Call

    Mon, Nov 10, 2025 · 8:30 AM ET

    Watch Transcript

  • Organon & (NYSE:OGN) Q2 2025 Earnings Call

    Tue, Aug 05, 2025 · 8:30 AM ET

    Watch Transcript

Latest news

Organon Announces Quarterly Dividend

Oct 30, 2026

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Oct 19, 2026

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Oct 16, 2026

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Oct 1, 2026

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

Sep 28, 2026

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Sep 14, 2026

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Aug 11, 2026

New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

Jul 24, 2026

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Jul 16, 2026

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting

Jul 7, 2026

All Organon & Co. news

Decks

Organon & Co. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
42 in the last 12 months · 55 in all · newest Oct 30, 2026 · oldest 2025
Calls
19 calls with a replay · 19 with a transcript · latest Feb 12, 2026
Decks
23 decks · latest Jun 9, 2026

Where Organon & Co. is listed

ListingExchangeCountryCurrency
NYSE:OGN · Home listingNYSEUnited StatesUSD
gettex:7XPgettexGermanyEUR
BMV:OGNBMVMexicoMXN
Tradegate:7XPTradegateGermanyEUR
LS Exchange:A3CPKPLS ExchangeGermanyEUR
BOATS:OGNBOATSUnited StatesUSD
BIVA:OGNBIVAMexicoMXN
Lang & Schwarz:A3CPKPLang & SchwarzGermanyEUR
LSE:0A9WLSEUnited KingdomUSD
Milan:1OGNMilanItalyEUR
EUROTLX:4OGNEUROTLXItalyEUR
Frankfurt:7XPFrankfurtGermanyEUR
Hamburg:7XPHamburgGermanyEUR
Stuttgart:7XPStuttgartGermanyEUR
Dusseldorf:7XPDusseldorfGermanyEUR
Munich:7XP · This pageMunichGermanyEUR

Log in to ask 6ix AI your own questions about Organon & Co.